Olaratumab + Gemcitabine + Docetaxel + Placebo
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma
Trial Timeline
Mar 1, 2016 → Apr 27, 2021
NCT ID
NCT02659020About Olaratumab + Gemcitabine + Docetaxel + Placebo
Olaratumab + Gemcitabine + Docetaxel + Placebo is a phase 1/2 stage product being developed by Eli Lilly for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02659020. Target conditions include Soft Tissue Sarcoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02659020 | Phase 1/2 | Completed |
Competing Products
20 competing products in Soft Tissue Sarcoma